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ABSTRACT
Objective To assess evidence from randomised clinical
trials about the effectiveness of extracts of Boswellia
serrata (frankincense).
Design Systematic review.
Data sources Electronic searches on Medline, Embase,
Cinahl, Amed, and Cochrane Library. Hand searches of
conference proceedings, bibliographies, and
departmental files.
ReviewmethodsAllrandomisedclinicaltrialsofBserrata
extract as a treatment for any human medical condition
were included and studies of B serrata preparations
combinedwithotheringredientswereexcluded.Titlesand
abstracts of all retrieved articles were read and hard
copies of all relevant articles were obtained. Selection of
studies, data extraction and validation were done by the
author. The Jadad score was used to evaluate the
methodological quality of all included trials.
Results Of 47 potentially relevant studies, seven met all
inclusion criteria (five placebo controlled, two with active
controls). The included trials related to asthma,
rheumatoid arthritis, Crohn’s disease, osteoarthritis, and
collagenous colitis. Results of all trials indicated that B
serrata extracts were clinically effective. Three studies
were of good methodological quality. No serious safety
issues were noted.
Conclusions The evidence for the effectiveness of B
serrata extracts is encouraging but not compelling.
INTRODUCTION
Whentheysawthestar,theyrejoicedexceedinglywith
great joy. And going into the house they saw the child
with Mary his mother, and they fell down and
worshiped him. Then, opening their treasures, they
offered him gifts, gold and frankincense and myrrh.
(Matthew 2, 10-11, English Standard Version)
Frankincense, also known as olibanum, is the resin
from the trees of the genus Boswellia, native to Arabia
and India. It has a long history of use—for example, in
religious ceremonies and for perfume production—
and its medicinalpropertieshave been appreciated for
millennia.
1 Recently, the pharmacological properties
and clinical effectiveness of Boswellia serrata have been
studied systematically.
The aim of this systematic review was to summarise
and critically evaluate the evidence from all rando-
mised clinical trials of B serrata extracts.
METHODS
Searches were done of Amed, Cinahl, Embase, and
Medline databases (on 18 August 2008, each from its
inception, using the Ovid Sp Interface), the Cochrane
Library, and our departmental files, including con-
ferenceproceedings.Foursearchterms(Boswellia.mp,
Boswelli/mesch, “Boswellia serrata”.mp, Frankin-
cense.mp) were constructed using a combination of
MeSH and free-word terms on the individual data-
bases.Resultswereinitiallyscreenedbytitletoexclude
any obviously irrelevant articles, and potential hits
were downloaded into Endnotes files. No language
restrictions were applied.
Clinical trials had to be randomised, include human
patients with any medical condition, and use B serrata
extractsasamonopreparation.Studiesofpreparations
containing B serrata in combination with other
ingredients,
23 non-randomised trials,
45 and abstracts
reporting incomplete data for evaluation were
excluded.
Data were extracted and validated in accord with
predefined criteria (table). Two independent reviews
assessedmethodologicalqualitywiththe Jadadscore.
6
A meta-analysis was not possible because of hetero-
geneity, so results are presented in narrative form.
RESULTS
Sevenrandomisedclinicaltrialswereincluded(fig1).
7-13
The table summarises key data. The studies were
published between 1998 and 2008 and most came
from India. Methodological quality was variable but
three trials reached the maximum on the Jadad
scale.
101113 Five trials were placebo controlled and two
were comparisons against active treatments. All studies
used oral administration of B serrata extracts.
Boswellia extracts showed some promise in treating
asthma,
7 rheumatoid arthritis,
8 Crohn’s disease,
9 knee
osteoarthritis,
101213 and collagenous colitis.
11 How-
ever,alltheincludedtrialshadflaws:themostcommon
limitations were small sample size and incomplete
reporting of data. The largest study included 102
patients, which is not large considering that this was a
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9 Crucially, little independent
replicationwasfound;foronlyoneofthefivedifferent
indications (osteoarthritis) had more than one rando-
mised clinical trial been published.
101213
Adverse effects of B serrata were minor and were
judged as not causally related to the treatment and not
markedly different from those noted in the placebo
groups(table).Diarrhoea,abdominalpain,andnausea
were reported in more than one study.
DISCUSSION
Collectively, these data seem to indicate that B serrata
extracts are effective in treating a range of conditions
caused or maintained by inflammatory processes. The
Key data from randomised clinical trials included in systematic review
First author
(year),
country
Condition
(sample
size)
Design
(Jadad
score)* Interventions Nature of extract†
Primary outcome
measure
Main results/effect
size‡
Adverse effects of
BSE (A) and control
intervention (B) Comment
Gupta
(1998),
India/
Germany
7
Asthma (80) DB,PC,2PG
(3)
(A) BSE (350 mg
3×day) for
6w e e k s ;( B )
placebo
“Boswelic acid containing
drug 300 mg”
Percentage of
patients showing
clinical
improvement
(A) 70% remission; (B)
27% remission§
(A) 2 patients
experienced stomach
pain, hyperacidity,
nausea; (B) no
information
Group (A) had more
severe asthma than
group (B); other
endpoints also
suggested efficacy of
BSE
Sander
(1998),
Germany
8
Rheumatoid
arthritis(37)
DB PC, 2 PG
(2)
A)BSE(3600mg
9×day) for
12 weeks; (B)
placebo; both
groups also
received
conventional
drugs
H15§ Ritchie Index Non-significant trend in
favour of BSE§
(A) Stomatitis (1
patient);(B)eczema(1
patient), nausea (1
patient), increase of
joint pain (1 patient)
Report only relates to
subset of patients
from larger
unpublished study
Gerhardt
(2001),
Germany/
Austria
9
Crohn’s
disease
(102)
DB, 2PG,
non-
inferiority
(3)
(A)BSE(3.6gper
day)for8weeks;
(B) mesalazine
(4.5 per day)
H15‡ Crohn’sA c t i v i t y
Index (CAI)
Non-inferiority of BSE
confirmed: (A) CAI from
301 (63) to 192 (114);
(B) from 282 (72)to163
(96)
(A) Nocausallyrelated
adverseeffects;(B)13
causally related
adverse effects
Datarefertointention
to treat analysis
Kimmatkar
(2003),
India
10
Osteoarthri-
tis of the
knee (30)
DB, PC,
crossover
(5)
(A) BSE (333 mg
per day) for
8w e e k s ;( B )
placebo
“Standardized extract of
Boswellia serrata gum:
minimum 65% organic acids
or min 40% total BA. Main
components of BA: 11-keto-β
BA—6.44%, 3-O-Acetyl-11-
ketoβ BA—2%, β-BA—
18.51%, 3-O-Acetylβ BA—
8.58%, α-BA—6.93%, 3-O-
Acetyl-α-BA—1.853%.”
Pain, function
(VAS)
Significant intergroups
differences in favour of
BSE; intergroup
difference for pain 2.3
(0.61)
(A) Diarrhoea (1
patient), epigastric
pain, nausea (1
patient); (B) no
information
Authorsstatethatthe
differences are
clinically relevant
Madisch
(2007),
Germany
11
Collagenous
colitis (31)
RCT, DB, PC,
2P G( 5 )
(A) BSE (400 mg
3×day) for
6w e e k s ;( B )
placebo
“High performance liquid
chromatography analysis…
21.2 mg 11-keto-β-boswellia
acid, 27.3 mg α-boswellia
acid, 50.9 mg β-boswellia
acid, 11.3 mg acetyl-11-keto-
β-boswellia acid, 9.8 mg
acetyl-α-boswellia acid,
28.7 mg acetyl-β-boswellia
acid.”
Percentage of
patients with
remission
(A)64%remission(95%
CI 30.8 to 89.1, ITT
44%); (B) 27% (7.7 to
55.1, 27%)
(A) Dizziness,
hypoglycaemia, lack
of appetite, diarrhoea
(1 patient), bacterial
enteritis (1 patient);
(B) no information
Other outcome
measures (such as
stool frequency) also
suggest efficacy of
BSE
Sontakke
(2007),
India
12
Osteoarthri-
tis of the
knee (66)
RCT, open,
active
control, 2PG
(2)
(A) BSE (333 mg
3×day) for
6 months; (B)
valdecoxib
(10 mg, 1×day)¶
“Standardized extract of BSE
having minimum 40% total
BA. Main components of BA:
11-keto-β BA—6.44%, 3-O-
Acetyl-β BA—8.58%, alpha
BA—6.93% and 3-O-acetyl α
BA—1.853%.”
WOMAC scale Pain: (A) from 245.3
(77.6) to 82.9 (62.3) at
6 months; (B) from
246.0 (71.4) to 85.4
(68.9)
(A) Diarrhoea (1
patient); (B) no
adverse effects
1 month after
discontinuation of
therapy, patients in
group (A) maintained
benefit while those in
(B) deteriorated
Sengupta
(2008),
India
13
Osteoarthri-
tis of the
knee (75)
RCT, DB, PC,
3P G( 5 )
(A) BSE (100 mg
per day) for
90 days, (B) BSE
(250 mg per
day),(C)placebo
“5-Loxin(R), novel B. serrata
enriched to 30%, 3-O-acetyl-
11-keto-β-boswellic acid
(AKBA) (US-Patent
publication no.: 2004/
007306041).”
Pain (VAS),
Lequesne Index,
WOMAC Index
Significant inter-group
differences in favour of
(A) and (B) versus (C);
pain: (A) from 57.1 (8.7)
to 21.4 (7.1); (B) from
55.6 (9.3) to 14.2 (6.8);
(C) from 55.9 (12.0) to
41.8 (16.0)
Diarrhoea, nausea,
abdominalpain,fever,
weakness; evenly
distributed between
groups
Other outcome
measures also
suggest efficacy of
BSE
BA=boswellic acid; BSE=Boswellia serrata extract; CRP=C-reactive protein; DB=double blind; ESR=erythrocyte sedimentation rate; MC=multicentre; PC=placebo controlled; PG=parallel
groups; VAS=visual analogue scale; WOMAC=Western Ontario and McMasters Universities Osteoarthritis Index.
*Studies were superiority trials unless otherwise stated.
†Inverted commas indicate quote from publication.
‡Values are mean (SD) unless otherwise indicated; values in parentheses not identified in Sontakke study.
§No further information provided.
¶Trial done before withdrawal of valdecoxib from market.
RESEARCH
page 2 of 4 BMJ | ONLINE FIRST | bmj.comresults of non-randomised studies and trials of herbal
mixturescontaining Bserrata , which failedto meet the
inclusion criteria for this systematic review, tend to
point in the same direction.
4514B serrata has been used
traditionally against inflammatory diseases.
15 Its main
pharmacologically active ingredients are α and β
boswellic acid, as well as other pentacyclic triterpenic
acids.
16 These compounds have been shown to inhibit
pro-inflammatory processes by their effects on 5-
lipooxygenase and cyclo-oxygenase and on the com-
plement system.
1517
The evidence evaluated here may be encouraging,
but it is not convincing. Not enough large randomised
clinical trials have been published for any condition.
The medications used in these trials cannot be directly
compared in terms of contents and strength. The
pharmacokineticsandoptimaldoseofBserrataextracts
are largely unknown; usually 600-3000 mg gum resin
per day or equivalents are recommended for oral
intake.
18 Source of funding or sponsorship was undi-
sclosed in all but one trial.
13
Dozens of B serrata preparations for oral intake are
commerciallyavailable.Themajorityarenotregulated
as medicines but sold as food supplements. Fortu-
nately,thesafetyprofileofBserrataseemsgood.
18Inthe
included trials, no serious, long term, or irreversible
adverse effects were noted. Other data indicate that
mild adverse effects such as nausea, acid reflux, and
gastrointestinal upset may occasionally occur.
18 No
evidence of serious interactions with drugs has been
noted.
18 However, absenceof evidence is not the same
asevidenceofabsence,whichisparticularlyrelevantin
herbalmedicine,wherepharmacovigilanceisoftenless
than optimal.
19
Many of the medical, quasimedical, or cosmetic
claims made implicitly or explicitly for Bs e r r a t a
products are not supported by the available evidence.
Their trade names speak for themselves: regeneration
body balm, intensive eye serum, supernatural instant
youth serum, lifting and firming body lotion, joie de
vivrefacelotion,radianceanti-ageing,jointandmuscle
balm, ultra inflammactin, to name a few. Currently
morethanonemillionwebsiteson“Frankincense”and
half a million on “Boswellia” exist (Google searches,
November 2008); the majority fail to offer reliable
information on its medicinal uses.
This systematic review has several limitations.
Although the search strategy was thorough, some
randomisedclinicaltrialsmightnothavebeenlocated.
A positive publication bias cannot be excluded—
complementary medicine journals rarely publish
negative results.
20 The overall picture generated by a
systematicreviewcouldthusbefalsepositive.Methods
forassessingthe extentofpublicationbiasarenot very
effective if, as in the present case, few trials are
available.Mandatoryworldwideregistrationofclinical
trials in herbal medicine seems unlikely to happen at
present.Incompletereportingisanotherproblem.One
trial related to a subset of patients from a larger
multicentrestudythathasneverbeenpublishedinfull.
8
Crucially, the paucity of rigorous studies prevents any
definitivejudgementabouttheeffectivenessofBserrata
extracts.
In conclusion, it might be tempting to buy “instant
youth”intheformofaBserrataproductforChristmas,
butsadlytheevidenceforthisclaimisnonexistent.For
other indications, evidence is encouraging but not
convincing. The existing data do, however, warrant
further investigation of this herbal medicine.
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